EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieÄquivalenzstudieOpen Access · CC BY 4.0

Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity: a randomised, controlled trial (SORAIRO trial)

Yuki Imai, Michihito Kono, Tomonori Ishii, Toshihisa Kojima, Shintaro Hirata, Yoshiya Tanaka, Eiichi Tanaka, Koichiro Ohmura, Shunsuke Okamoto, Rumiko Matsumoto, Yuri Sato, Takashi Yamamura und 2 weitere

Annals of the Rheumatic Diseases · 2026-04 · 85 (4) · 609-619

DOI: 10.1016/j.ard.2026.02.004 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of the Rheumatic Diseases, 2026-04. Verfasst von Yuki Imai und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Methotrexate, Antirheumatic Agents, Tumor Necrosis Factor-alpha. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taisho Toyama Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: This study aimed to assess the noninferiority of spacing a tumour necrosis factor (TNF) inhibitor or reducing the methotrexate dose with continued treatment in patients with rheumatoid arthritis. METHODS: The SORAIRO trial was a multicentre, open-label, randomised, noninferiority study. Patients who had been in remission or low disease activity based on the Clinical Disease Activity Index (CDAI) in the preceding phase III trial of ozoralizumab, a next-generation TNF inhibitor, were enrolled. The precalculated sample size was 141. Patients were randomised into continued treatment, ozoralizumab spacing, or methotrexate dose reduction groups. The primary endpoint was a noninferiority of low disease activity maintenance at week 48 with a prespecified noninferiority margin of -18%. RESULTS: A total of 144 patients were analysed. The mean age was 58.2 years, 75.0% were female, and the mean CDAI was 2.70 with 61.8% in remission. The low disease activity at week 48 was 97.9% in the continued treatment group, 79.2% in the ozoralizumab spacing group (difference, -21.6; 95% CI, -39.9 to -5.7), and 72.7% in the methotrexate dose reduction group (difference, -30.4; 95% CI, -54.0 to -10.5). In the baseline remission subgroup, remission maintenance rates were comparable in the 3 groups (77.4%, 76.7%, 79.2%, respectively). No significant differences were demonstrated in changes in the Health Assessment Questionnaire Disability Index and modified total Sharp score. Adverse events occurred in 68.0%, 59.2%, and 58.0%, respectively. CONCLUSIONS: Treatment tapering may not be feasible in patients with low disease activity, whereas both extending the TNF inhibitor interval and reducing the methotrexate dose may be reasonable options for patients in remission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidMethotrexateAntirheumatic AgentsTumor Necrosis Factor-alphaAntibodies, Monoclonal, HumanizedHumansFemaleMiddle AgedMaleRemission InductionTreatment OutcomeAgedSeverity of Illness IndexDrug TaperingAdultDrug Administration Schedule

Substanzen

MethotrexateAntirheumatic AgentsTumor Necrosis Factor-alphaAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Department of Haematology and Rheumatology, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan.
  • Department of Orthopaedic Surgery, National Hospital Organization Nagoya Medical Centre, Nagoya, Japan.
  • Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.
  • The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan; Department of Molecular Targeted Therapeutics, School of Medicine, University of Occupational and Enviro…

Förderung

  • Taisho Toyama Pharmaceutical Company

Zitieren

APA

Imai, Y., Kono, M., Ishii, T., Kojima, T., Hirata, S., Tanaka, Y., Tanaka, E., Ohmura, K., Okamoto, S., Matsumoto, R., Sato, Y., Yamamura, T., Takeuchi, T., & Kaneko, Y. (2026). Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity: a randomised, controlled trial (SORAIRO trial). Annals of the Rheumatic Diseases, 85(4), 609-619. https://doi.org/10.1016/j.ard.2026.02.004

Vancouver

Imai Y, Kono M, Ishii T, Kojima T, Hirata S, Tanaka Y, et al. Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity: a randomised, controlled trial (SORAIRO trial). Annals of the Rheumatic Diseases. 2026;85(4):609-619. doi:10.1016/j.ard.2026.02.004

BibTeX
@article{Imai2026,
  author = {Imai, Yuki and Kono, Michihito and Ishii, Tomonori and Kojima, Toshihisa and Hirata, Shintaro and Tanaka, Yoshiya and Tanaka, Eiichi and Ohmura, Koichiro and Okamoto, Shunsuke and Matsumoto, Rumiko and Sato, Yuri and Yamamura, Takashi and Takeuchi, Tsutomu and Kaneko, Yuko},
  title = {Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity: a randomised, controlled trial (SORAIRO trial)},
  journal = {Annals of the Rheumatic Diseases},
  year = {2026},
  volume = {85},
  number = {4},
  pages = {609--619},
  doi = {10.1016/j.ard.2026.02.004}
}
Kostenlos starten →